OR WAIT null SECS
This arrangement was approved by the shareholders at BELLUS on June 16, 2023, according to a company press release.
GSK announced on June 28, 2023 that it has completed the acquisition of BELLUS Health, a late-stage Candian biopharmaceutical company, through a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act. This arrangement was approved by the shareholders at BELLUS on June 16, 2023, according to a company press release.
The acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in Phase II development for the first-line treatment of adult patients with refractory chronic cough (RCC). Further, BELLUS has announced the cancellation of its annual shareholder meeting, which was scheduled for June 30, 2023.
“The acquisition of BELLUS is highly synergistic with GSK’s expertise in respiratory medicines and is further supported by GSK’s leading R&D, manufacturing, and commercialization capabilities,” said Luke Miels, chief commercial officer, GSK, in the press release. “We are now focused on progressing camlipixant through Phase III trials to offer a therapeutic option for RCC patients as soon as possible.”